SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA 2004 Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 11891199.
  • 2
    Siris ES, Brenneman SK, Miller PD, Barrett-Connor E, Chen YT, Sherwood LM, Abbott TA 2004 Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50–64 and 65 and older: Results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res 19: 12151220.
  • 3
    Bolotin HH, Sievanen H 2001 Inaccuracies inherent in dual-energy X-ray absorptiometry in vivo bone mineral density can seriously mislead diagnostic/prognostic interpretations of patient-specific bone fragility. J Bone Miner Res 16: 799805.
  • 4
    Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr 2004 Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc 52: 15431548.
  • 5
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333: 14371443.